MGC Pharmaceuticals Ltd.

Issue of New Shares Completed in 2021

10 February 2022

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to make a formal notification regarding share issues that have occurred following the Company's IPO listing on the London Stock Exchange on 9 February 2021, and prior to the UK Placing in December 2021.

As the Company is dual listed, requisite compliance documentation for the quotation of these new shares lodged with on the Australian Securities Exchange (ASX), being Appendix 2As "Application for Quotation Securities", were also released on RNS.

MGC is now applying for admission of these shares to the FCA's Official List, and for trading on the Main Market of the LSE, as such, MGC Pharma wishes to advise that it issued 194,010,702 new shares between 4 March 2021 and 24 November 2021 for which it is applying for admission to trading on the LSE from 8:00am (GMT) on 16 February 2022.

As noted above, these shares are not in addition to previously announced share issues during the period stated above, and this announcement is being made for UK Regulatory listing and disclosure requirements only.

--Ends--

Authorised for release by the Chairman, for further information please contact:

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma